Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Maier, Melanie ^a   Liebert, Uwe G ^a   Wittekind, Christian ^a   Kaiser, Thorsten ^a   Berg, Thomas ^a   Wiegand, Johannes ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; NUCLEOSIDE; NUCLEOTIDE;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LIMIT OF DETECTION; LONG TERM CARE; MALE; MEDICAL DEVICE; MINIMAL RESIDUAL VIREMIA; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS CARRIER; VIRUS LOAD; VIRUS RESISTANCE; ADULT; DRUG EFFECTS; GERMANY; HEPATITIS B, CHRONIC; INCIDENCE; NEOPLASM, RESIDUAL; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; ANTIVIRAL AGENTS; FEMALE; GERMANY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; MALE; NEOPLASM, RESIDUAL; NUCLEOSIDES; NUCLEOTIDES; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIREMIA;

EID: 84879516981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067481     Document Type: Article

References (23)

1. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, et al. (2011) [Prophylaxis, diagnosis and therapy of hepatitis B virus infection- the German guideline]. Z Gastroenterol 49: 871-930.
2. European Association For The Study Of The Liver, (2012) EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185 S0168-8278(12)00167-5 [pii];10.1016/j.jhep.2012.02.010 [doi].
3. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 354: 1011-1020.
4. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 354: 1001-1010.
5. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, et al. (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 357: 2576-2588.
6. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, et al. (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 359: 2442-2455.
7. Chang TT, Lai CL, Kew YS, Lee SS, Coelho HS, et al. (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 51: 422-430.
8. Marcellin P, Buti M, Gane E, Krastev Z, Flisiak R, et al. (2011) Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 54: 1011A.
9. Heathcote EJ, Marcellin P, Buti M, Gane E, de Man RA, et al. (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 140: 132-143.
10. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, et al. (2011) Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 106: 1264-1271.
11. Schiff ER, Lee SS, Chao YC, Kew YS, Bessone F, et al. (2011) Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 9: 274-276.
12. Iloeje UH, Yang HI, Su J, Jen CL, You SL, et al. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686.
13. Locarnini S, (2005) Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 25Suppl 1: 9-19 10.1055/s-2005-915645 [doi].
14. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, et al. (2011) Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 54: 443-451.
15. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, et al. (2010) Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139: 1207-1217.
16. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, et al. (2012) Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 143: 619-628 S0016-5085(12)00802-5 [pii];10.1053/j.gastro.2012.05.037 [doi].
17. Ismail AM, Sivakumar J, Anantharam R, Dayalan S, Samuel P, et al. (2011) Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantification. J Clin Microbiol 49: 3215-3221 JCM.00915-11 [pii];10.1128/JCM.00915-11 [doi].
18. Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, et al. (2007) Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol 45: 3948-3953 JCM.01180-07 [pii];10.1128/JCM.01180-07 [doi].
19. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM, (2008) Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 46: 1716-1723 JCM.01248-07 [pii];10.1128/JCM.01248-07 [doi].
20. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM, (2010) Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 48: 3641-3647 JCM.01306-10 [pii];10.1128/JCM.01306-10 [doi].
21. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, et al. (2013) Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis b with high baseline viral load (>/ = 9 log10 copies/mL). Hepatology. 10.1002/hep.26277 [doi].
22. Gish R, Jia JD, Locarnini S, Zoulim F, (2012) Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 12: 341-353 S1473-3099(11)70314-0 [pii];10.1016/S1473-3099(11)70314-0 [doi].
23. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, et al. (2011) Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 60: 1109-1116 gut.2010.221846 [pii];10.1136/gut.2010.221846 [doi].